Study of PembrolizumAb combiNeD With Cisplatin or carbOplatin and Etoposide in Treatment naïve Advanced meRkel Cell cArcinoma (MCC)
Clinical trial NCT06086288 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT06086288
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-11-01
- Primary completion
- 2027-12-01
- Enrollment
- 35
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.